# 2026-08-27

## ✅ 0 instructions awaiting your approval in IBKR

The IBKR approval queue is empty. Nothing was created this cycle, nothing is
waiting for a tap, and nothing has executed.

## Reconciliation since the last run

Nothing to reconcile. `get_order_instructions` returned an empty queue and every
`instruction` entry in `trade_log.jsonl` was already resolved on an earlier
cycle — no approval, no decline and no expiry happened since yesterday.

## ⚠ A thesis was dropped on its facts, not its price — CORT

Phase A's CORT thesis rests on **"2026 revenue guidance of $900M–$1.0B stands"**
and on there being *no* company-disclosed catalyst behind the stock's 36% 60-day
advance. Both are contradicted by Corcept's own Q2 2026 report: guidance was
**raised to $1.1B–$1.2B** (from $950M–$1,050M) on Q2 revenue of **$256.1M, up
32%**, including **$47.6M from newly launched LIFYORLI (relacorilant)** — and the
stock rose roughly 20% on that release. That raise *is* the catalyst the thesis
says does not exist.

Also noted, though not the basis for the drop: relacorilant was **approved** as
Lifyorli for platinum-resistant ovarian cancer on 2026-03-25 and is selling,
while the thesis reads the disclosed news as uniformly bad on the strength of the
(real, separate) 2025-12-31 hypercortisolism CRL. That resubmission now carries a
PDUFA date of **2026-12-17**.

This thesis is wrong **in your favour** — Corcept is doing better than Phase A
believes — and it was dropped anyway. A thesis contradicted on a figure the
company disclosed is invalid regardless of which way the price moved. The price
check alone (−0.65%) would have waved it straight through.

**This did not sell anything.** The stop-loss and take-profit checks ran first
and neither triggered. Dropping CORT removed it as a *top-up candidate* only; the
0.8489-share position is still held and Phase A will re-screen it tonight.

Sources: [Simply Wall St](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/why-corcept-therapeutics-cort-is-up-198-after-boosting-2026)
· [Corcept IR Q2 2026](https://corcept.gcs-web.com/news-releases/news-release-details/corcept-therapeutics-announces-second-quarter-financial-4)
· [ChartMill](https://www.chartmill.com/news/CORT/Chartmill-52125-Corcept-Therapeutics-NASDAQCORT-Surges-21-After-Q2-Earnings-Beat-and-Raised-Guidance)
· [Drugs.com — Lifyorli approval history](https://www.drugs.com/history/lifyorli.html)

## Loss limits

Clear — **$0.00 realized** so far in the current Chicago trading week (week began
2026-08-24), against a 5% daily / 10% weekly limit on $542.44 starting capital.
New entries and top-ups are **not** halted.

Partial by construction: this only sees the one account the connector is attached
to. `YOUR_OTHER_ACCOUNT_ID_HERE` could not be queried and must **not** be read as
having come back clean.

## Held positions — stop-loss / take-profit

All quotes live (REALTIME). No stop triggered, no tier fired.

| Symbol | Avg cost | Fresh price | Drawdown | Stop % used | Status |
|---|---|---|---|---|---|
| MSFT | $503.62 | $493.57 | 1.99% | 5.00% | holding |
| CORT | $121.75 | $119.00 | 2.26% | 5.37% | holding |
| DELL | $497.02 | $464.82 | 6.48% | 11.00% | holding |
| ALAB | $307.23 | $302.58 | 1.51% | 12.52% | holding |

No take-profit tier has fired on any of these this holding period — all four are
below cost, so the 15% / 30% / 50% tiers are nowhere near.

> Reminder: there is **no resting stop at the broker**. `create_order_instruction`
> has no stop order type, so these are evaluated once a day, and even a trigger
> only produces an instruction awaiting your tap.

## Candidates considered

**6 new entries skipped on capacity** — 4 of 4 concurrent positions already held,
so `open_slots = 0`. Skipped without a staleness re-check; this is scarcity, not a
judgment on the theses:
MRVL (medium), INTC (low), AAOI (low), NBIS (low), AMD (low), LITE (low).

**4 top-up candidates evaluated:**

- **CORT** (low) — dropped by the fact check, above.
- **MSFT** (high) — facts confirmed against the FY26 Q4 print (revenue $90.01B vs
  $87.62B expected, adj. EPS $4.74 vs $4.24, Azure +43%, Cloud past $100B). No
  top-up: position $215.00 is already above the $105.04 target for its tier.
- **DELL** (medium) — facts confirmed against Q1 FY27 (revenue $43.8B +88%, AI
  server revenue $16.1B, non-GAAP EPS $4.86, record $51.3B AI backlog, FY27
  guidance raised to $165–169B with ~$60B AI servers). No top-up: only $2.18 of
  headroom, below the $6.30 minimum.
  *Correction:* the thesis dates the fiscal Q2 print to 2026-08-28; the scheduled
  call is the week of 2026-09-01, so that binary catalyst is still ahead of you.
- **ALAB** (low) — facts confirmed against Q2 2026 (record revenue $392.4M +104%,
  Q3 guide $540–560M). No top-up: position $64.42 already above the $31.51 target.

## Housekeeping

Ran 08:36–08:41 Central, inside the 08:30–15:00 regular-session guard. Account
identity was **not** verified — no connector endpoint returns one. The fingerprint
(net liquidation $525.19, 4 positions: ALAB, CORT, DELL, MSFT) is a tripwire only
and cannot distinguish two accounts of similar size.

`trade_log.jsonl` is the source of truth; this file is a convenience view. If the
two disagree, trust `trade_log.jsonl`.
